Abstracts tagged "Kawasaki disease and aspirin"

Abstract Number: 2899 • 2014 ACR/ARHP Annual Meeting
High Dose Aspirin for Treating Kawasaki Disease – Outdated Myth or Effective Aid?
Gil Amarilyo¹, Yael Koren², Dafna Brik Simon³, Maskit Bar-Meir⁴, Hilla Bahat⁵, Mona Hanna Helou⁶, Amir Mendelson⁷, Yackov Berkun⁸, Eli Eisenstein⁹, Yonatan butbul Aviel¹⁰, Galia Barkai¹¹, Yoav Bolkier¹¹, Shai Padeh¹¹, Philip J. Hashkes¹², Riva Brik¹⁰, Liora Harel¹ and Yosef Uziel¹³, ¹Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikvah, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Schneider Children's Medical Center of Israel, Petach Tikvah, Israel, ⁴Infectious Diseases, Shaare-Zedek Medical Center, Jerusalem, Israel, ⁵Pediatrics, Assaf Harofeh Medical Center, Zerifin, Israel, ⁶Pediatrics B Department, Rambam Medical Center, Haifa, Israel, ⁷Pediatric Rheumatology, Meir Medical Center, Kfar Saba, Israel, ⁸Pediatrics and Pediatric Rheumatology, Hadassah Hebrew University Medical Center, Jerusalem, Israel, ⁹Dept of Pediatrics, Hadassah Hebrew University Medical Center, Jerusalem, Israel, ¹⁰Pediatric Rheumatology, Rambam Medical Center, Haifa, Israel, ¹¹Sheba Medical Center, Tel-Hashomer, Israel, ¹²Pediatrics, Shaare-Zedek Medical Center, Jerusalem, Israel, ¹³Pediatric Rheumatology Unit , Department of Pediatrics, Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Kawasaki disease (KD) is generally treated with intravenous immunoglobulin (IVIG) together with high anti-inflammatory doses of acetyl salicylic acid (ASA), which is subsequently switched…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].